Literature DB >> 22530907

Prodrug strategies in ocular drug delivery.

Megha Barot1, Mahuya Bagui, Mitan R Gokulgandhi, Ashim K Mitra.   

Abstract

Poor bioavailability of topically instilled drug is the major concern in the field of ocular drug delivery. Efflux transporters, static and dynamic ocular barriers often possess rate limiting factors for ocular drug therapy. Different formulation strategies like suspension, ointment, gels, nanoparticles, implants, dendrimers and liposomes have been employed in order to improve drug permeation and retention by evading rate limiting factors at the site of absorption. Chemical modification such as prodrug targeting various nutrient transporters (amino acids, peptide and vitamin) has evolved a great deal of interest to improve ocular drug delivery. In this review, we have discussed various prodrug strategies which have been widely applied for enhancing therapeutic efficacy of ophthalmic drugs. The purpose of this review is to provide an update on the utilization of prodrug concept in ocular drug delivery. In addition, this review will highlight ongoing academic and industrial research and development in terms of ocular prodrug design and delivery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22530907      PMCID: PMC4407659          DOI: 10.2174/157340612801216283

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  170 in total

1.  Regulation of glucose transporters during development of the retinal pigment epithelium.

Authors:  Y Ban; L J Rizzolo
Journal:  Brain Res Dev Brain Res       Date:  2000-05-11

2.  Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs.

Authors:  Riku Niemi; Juhani Huuskonen; Krista Laine; Tomi Järvinen
Journal:  Int J Pharm       Date:  2005-05-13       Impact factor: 5.875

3.  Na(+)-dependent L-arginine transport in the pigmented rabbit conjunctiva.

Authors:  K Hosoya; Y Horibe; K J Kim; V H Lee
Journal:  Exp Eye Res       Date:  1997-10       Impact factor: 3.467

4.  Solid lipid microparticles for the stability enhancement of a dopamine prodrug.

Authors:  Alessandro Dalpiaz; Barbara Cacciari; Matteo Mezzena; Mariangela Strada; Santo Scalia
Journal:  J Pharm Sci       Date:  2010-11       Impact factor: 3.534

5.  Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.

Authors:  Jwala Jwala; Sai H S Boddu; Sujay Shah; Suman Sirimulla; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-04       Impact factor: 2.671

6.  Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.

Authors:  Banmeet S Anand; Suresh Katragadda; Yasser E Nashed; Ashim K Mitra
Journal:  Curr Eye Res       Date:  2004 Aug-Sep       Impact factor: 2.424

Review 7.  Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: clinical benefits in the treatment of glaucoma.

Authors:  S Melamed
Journal:  Drugs Exp Clin Res       Date:  2002

8.  Physicochemical characterization of high- and low-melting phenylephrine oxazolidines.

Authors:  Y Qiu; R D Schoenwald; J K Guillory
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

9.  Involvement of reduced folate carrier 1 in the inner blood-retinal barrier transport of methyltetrahydrofolate.

Authors:  Ken-ichi Hosoya; Keiko Fujita; Masanori Tachikawa
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

10.  Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma.

Authors:  A I Mandell; F Stentz; A E Kitabchi
Journal:  Ophthalmology       Date:  1978-03       Impact factor: 12.079

View more
  8 in total

1.  Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation.

Authors:  Shallu Kutlehria; Imran Vhora; Arvind Bagde; Nusrat Chowdhury; Gautam Behl; Ketan Patel; Mandip Singh
Journal:  Pharm Res       Date:  2018-04-16       Impact factor: 4.200

2.  In vivo drug delivery via contact lenses: The current state of the field from origins to present.

Authors:  Liana D Wuchte; Stephen A DiPasquale; Mark E Byrne
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-18       Impact factor: 5.062

Review 3.  Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases.

Authors:  Cinzia Rapino; Daniel Tortolani; Lucia Scipioni; Mauro Maccarrone
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  Investigating the Effect of Esterification on Retinal Pigment Epithelial Uptake Using Rhodamine B Derivatives.

Authors:  Chandima Bulumulla; Ruvanthi N Kularatne; Timothy Catchpole; Alison Takacs; Abigail Christie; Alexa Gilfoyle; Timothy D Nguyen; Mihaela C Stefan; Karl G Csaky
Journal:  Transl Vis Sci Technol       Date:  2020-05-19       Impact factor: 3.283

5.  Intravitreal Application: Physicochemical Properties of Drugs Dissolved in Silicone Oils of Different Density in Comparison to the Porcine Vitreous Body.

Authors:  Maximilian Hammer; Sonja K Schickhardt; Patrick R Merz; Ramin Khoramnia; Alexander F Scheuerle; Walter Mier; Philipp Uhl; Gerd U Auffarth
Journal:  Pharmaceutics       Date:  2022-06-28       Impact factor: 6.525

6.  A convenient and eco-friendly cerium(III) chloride-catalysed synthesis of methoxime derivatives of aromatic aldehydes and ketones.

Authors:  Iván Cortés; Teodoro S Kaufman; Andrea B J Bracca
Journal:  R Soc Open Sci       Date:  2018-05-23       Impact factor: 2.963

Review 7.  Multivalent Carbonic Anhydrases Inhibitors.

Authors:  Fabrizio Carta; Pascal Dumy; Claudiu T Supuran; Jean-Yves Winum
Journal:  Int J Mol Sci       Date:  2019-10-28       Impact factor: 5.923

8.  SG-SP1 Suppresses Mast Cell-Mediated Allergic Inflammation via Inhibition of FcεRI Signaling.

Authors:  Min-Jong Kim; In-Gyu Je; Jaeyoung Song; Xiang Fei; Soyoung Lee; Huiseon Yang; Wonku Kang; Yong Hyun Jang; Seung-Yong Seo; Sang-Hyun Kim
Journal:  Front Immunol       Date:  2020-01-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.